Patents Assigned to on behalf of the Walter Reed Army Institute Research
  • Combination purified inactivated vaccine for flaviviruses
    Patent number: 10086061
    Abstract: Immunogenic compositions comprising one or more inactivated dengue viruses and one or more inactivated non-dengue flaviviruses and methods of making and using thereof are provided.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: October 2, 2018
    Assignee: The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research
    Inventors: Stephen J. Thomas, Kenneth H. Eckels, Joseph R. Putnak
  • Triazine compounds and compositions thereof and methods for treating malaria and chemoprophylaxis
    Patent number: 9700562
    Abstract: Disclosed herein are triazine compounds and methods of making and using thereof to treat malaria, provide chemoprophylaxis, and/or treat or inhibit infection by one or more Plasmodium spp.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: July 11, 2017
    Assignee: The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research
    Inventors: Richard J. Sciotti, Gregory A. Reichard, Kristina M. Pannone, Victor E. Zottig
  • Substituted triazines for malaria treatment and chemoprophylaxis
    Patent number: 9334246
    Abstract: Disclosed herein are triazine compounds and methods of making and using thereof to treat malaria, provide chemoprophylaxis, and/or treat or inhibit infection by one or more Plasmodium spp.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 10, 2016
    Assignee: The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research
    Inventors: Richard J. Sciotti, Gregory A. Reichard, Kristina M. Pannone, Victor E. Zottig
  • Combinations of gene deletions for live attenuated shigella vaccine strains
    Patent number: 9320789
    Abstract: Shigella vaccine strains whose primary attenuating feature is deletion of the virG(icsA) gene and additional two or more deletions in setAB(shET1), senA(shET2), senB(shET2-2), stxAB, and msbB2 genes. Thus, the vaccine strain will have three or more deletions in the identified genes, will be safer, and will reduce or eliminate symptoms of fever and diarrhea in humans. The following specific vaccine strains have been constructed: WRSS3 (?senA, ?senB, ?virG, ?msbB2), WRSf2G15 (?virG, ?setAB, ?senA, ?senB, ?msbB2), and WRSd5 (?virG, ?stxAB, ?senA, ?senB, ?msbB2).
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: April 26, 2016
    Assignee: The United States of America as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research
    Inventors: Malabi Venkatesan, Ryan Ranallo, Shoshana Barnoy
  • Combinations of gene deletions for live attenuated vaccine strains
    Patent number: 8986708
    Abstract: Shigella vaccine strains whose primary attenuating feature is deletion of the virG(icsA) gene and additional two or more deletions in setAB(shET1), senA(shET2), senB(shET2-2), stxAB, and msbB2 genes. Thus, the vaccine strain will have three or more deletions in the identified genes, will be safer, and will reduce or eliminate symptoms of fever and diarrhea in humans. The following specific vaccine strains have been constructed: WRSS3 (?senA, ?senB, ?virG, ?msbB2), WRSf2G15 (?virG, ?setAB, ?senA, ?senB, ?msbB2), and WRSd5 (?virG, ?stxAB, ?senA, ?senB, ?msbB2).
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: March 24, 2015
    Assignee: The United States of America as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research
    Inventors: Malabi M. Venkatesan, Ryan T. Ranallo, Shoshana Barnoy
  • liver stage antigens
    Patent number: 8318183
    Abstract: The invention provides isolated liver stage Plasmodium polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1-48 and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the liver stage Plasmodium polypeptides of the invention, compositions comprising one or more liver stage Plasmodium polypeptides of the invention, methods for inducing an immune response against the liver stage Plasmodium polypeptides, and methods for treating and diagnosing liver stage malaria.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: November 27, 2012
    Assignees: Seattle Biomedical Research Institute, The United States of America, as Represented by the Secretary of the Army, on Behalf of the Walter Reed Army Institute of Research, Philadelphia Health & Education Corporation
    Inventors: Patrick Duffy, Stefan H. I. Kappe, Urszula Krzych, Donald G. Heppner, Lawrence W. Bergman, Vladislav A. Malkov, Alice Tarun, Jason P. Wendler, Igor Bacik
  • Malaria prime/boost vaccines
    Publication number: 20120014994
    Abstract: Described are vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from Plasmodium falciparum and purified recombinant protein vaccines such as RTS,S, in the context of appropriate adjuvants.
    Type: Application
    Filed: August 23, 2011
    Publication date: January 19, 2012
    Applicants: Crucell Holland B. V., behalf of the Walter Reed Army Institute of Research, GlaxoSmithKline Biologicals S. A.
    Inventors: Maria-Grazia Pau, Jaap Goudsmit, Joseph D. Cohen, Patrice M. Dubois, V. Ann Stewart, Donald Gray Heppner, JR.
  • Malaria prime/boost vaccines
    Publication number: 20090285879
    Abstract: Described are vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from Plasmodium falciparum and purified recombinant protein vaccines such as RTS,S, in the context of appropriate adjuvants.
    Type: Application
    Filed: December 23, 2008
    Publication date: November 19, 2009
    Applicants: Crucell Holland B.V., GlaxoSmithKline Biologicals S.A., on behalf of the Walter Reed Army Institute Research
    Inventors: Maria Grazia Pau, Jaap Goudsmit, Joseph D. Cohen, Patrice Dubois, V. Ann Stewart, Donald Heppner